Fig. 7
Inhibition of ITGA5 enhanced the efficacy of PD-L1 treatment in HCC. A Schematic of the design of ITGA5 inhibitor and immune checkpoint inhibitor treatments in an orthotopic HCC model established in mice pretreated with CCl4. B Bioluminescence imaging on days 2 and 10 in orthotopic HCC model mice subjected to the indicated treatments (n = 4). C Quantification of the bioluminescence signal. D OS curves of orthotopic HCC model mice following the indicated treatments. E Intrahepatic metastasis rates in each group. F Representative image of livers obtained from the indicated groups. Scale bar: 0.5 cm. G Quantification of the tumor diameter in the indicated groups. H Representative immunofluorescence images of ITGA5 (red)/α-SMA (green) and CD11b (green)/CD206 (red)/CD4 (gray)/CD8 (cyan) in orthotopic HCC tissues extracted from the indicated groups. Scale bar: 50 μm. *P < 0.05; **P < 0.01; ***P < 0.001